Selective kinase inhibitors have emerged as an important class of cancer therapeutics, and several such drugs are now routinely used to treat advanced stage disease. However, their clinical benefit is typically short-lived due to the relatively rapid acquisition of drug resistance following treatment response. Accumulating pre-clinical and clinical data pointing to a role for a heterogeneous response to treatment within a subpopulation of tumor cells that are intrinsically drug-resistant, such as "cancer stem cells". We have previously described an epigenetically-determined reversibly drug-tolerant subpopulation of cancer cells that share some properties with cancer stem cells. Here, we define a requirement for the previously established cancer stem cell marker ALDH (aldehyde dehydrogenase) in the maintenance of this drug-tolerant subpopulation. We find that ALDH protects the drug-tolerant subpopulation from the potentially toxic effects of elevated levels of reactive oxygen species (ROS) in these cells, and pharmacologic disruption of ALDH activity leads to accumulation of ROS to toxic levels, consequent DNA damage, and apoptosis specifically within the drug-tolerant subpopulation. Combining ALDH inhibition with other kinase-directed treatments delayed treatment relapse in vitro and in vivo, revealing a novel combination treatment strategy for cancers that might otherwise rapidly relapse following single agent therapy.
Introduction
Targeted cancer therapies that exploit the 'oncogene addiction' phenomenon observed in many tumor cells can be highly effective in the clinic (1) (2) (3) . However, responding tumors invariably recur due to acquired drug resistance, probably reflecting the outgrowth of a subpopulation of treatment-refractory cells. The maintenance of many cancers appears to require a subpopulation of tumor cells called cancer stem cells (CSCs) (4) , which have been identified in hematopoietic and solid malignancies (5) , and several studies have described a role for CSCs in drug resistance (6) Cancer cells are continuously exposed to extrinsic and intrinsic stresses that promote increased reactive oxygen species (ROS) and DNA damage (7) (8) (9) . The consequent accumulation of mutations in CSCs may render them more vulnerable to stress, especially as they enter S-phase. The activation of DNA damage response (10, 11) , increased expression of anti-apoptotic genes (12) , activation of the β-catenin pathway observed in leukemic stem cells (13) , and Notch and hedgehog pathways in prostate cancer cells (14) , are some of the mechanisms reported to underlie drug resistance in CSCs.
CSCs express various "markers", including CD44, CD133, and ALDH1A1, at levels substantially different from the bulk tumor cell population, and these markers are often used to isolate and functionally characterize CSCs. The association of CSC markers such as CD44 and CD133 with drug resistance has thus far been largely based on studies demonstrating reduced sensitivity of CSC marker-positive cells to chemotherapeutic drugs (15) or increased expression of these markers in treatment-resistant tumors (16, 17) . There have also been functional roles in drug resistance reported for these markers, including activation of ABC transporters and anti-apoptotic genes (18, 19) . Elevated ALDH1A1 is observed in CSCs of multiple cancer types (20) . ALDH proteins controls the oxidation of aldehydes to corresponding acids, and ALDH-mediated detoxification of toxic aldehyde intermediates produced in cancer cells treated with certain chemotherapy agents has been proposed to confer drug-resistant properties to ALDH1-positive tumor cells (21) . Here, we report that cancer cell subpopulations that tolerate the otherwise toxic drug exposures express elevated ALDH, which is critical for their survival. Inhibition of ALDH activity effectively eradicates this drug-tolerant subpopulation, revealing a potential beneficial effect of combination therapy that includes ALDH inhibition to delay cancer relapse.
Materials and Methods

Cell Culture
Human cancer cell lines were grown in RPMI media supplemented with sodium pyruvate, 10% fetal bovine serum and the antibiotics penicillin and streptomycin at 37 o C in 5% CO 2 .
Cell line identity is routinely monitored by SNP-based genotyping in the Genentech cell bank facility.
The Incucyte HD imaging system (Essen BioScience) was used to monitor cell growth in Author Manuscript Published OnlineFirst on May 8, 2014 ; DOI: 10.1158/0008-5472.CAN- phase contrast images of cells and uses a contrast based confluence algorithm to compute monolayer confluence of each image over multiple specified time points.
ALDH Activity Assays
A bodipy-labeled ALDH substrate (Aldefluor Kit, Stem Cell Technology) was used to detect ALDH activity. The substrate was diluted in RPMI media (5ul substrate/ml media) and added to adherent cells. After 30 minutes of incubation cells were washed twice with RPMI media and microfluorescence images were captured using an IncuCyte HD System (Essen BioScience) with a 10x objective. The quantification of ALDH high cells (~5% for was based on 16 images captured using the IncuCyte System with a 10x objective.
Flow Cytometry
The Aldefluor assay was used to detect ALDH activity in MKN-45 parental cells. ALDH 
Gene Expression Analysis
MKN-45 cells were plated on ten 15 cm dishes at 30x10 6 cells per plate, and. Following grown until 70% confluence and treated with 1uM crizotinib every 3 days for 4 weeks until DTPs were established. Non-drug-treated cells in a 15 cm dish were harvested 3 days after plating. RNA was extracted using a Qiagen RNeasy kit and RNA was amplified in 
Cell Viability Assays
Cells were fixed with 4% paraformaldehyde at the end of the assay period and viability was determined using the nucleic acid stain Syto60 (Life Technologies) diluted 1:5000 in water (23) . Fluorescence was measured using a SpectraMax M5 instrument (excitation 635nm and emission 695nm; Molecular Device). Viability was expressed as fraction of a no treatment control.
Generation of Drug-Tolerant Cells
MKN-45-and GTL-16-derived DTPs were generated by treating parental cells with 1uM crizotinib for 15-30 days. PC-9 cells were treated with 1uM erlotinib for 6-9 days for DTP generation. Drug concentrations used for DTP generation for all cell lines except GTL-16, EBC-1, and A549 cells is based on previous studies (22) . The appropriate concentration of each drug needed for DTP generation was established based on a dose response curve (Suppl. Table S3 ). The 200nM concentration of DS used for most of the cell lines used was based on an analysis of DS effects on MKN-45 and GTL-16 DTPs, where an effective cytotoxic DS concentration was empirically determined (Suppl. Fig. 3C ). In all cases media +/-drug was changed every three days. 
Immunoblotting
Proteins were extracted from cell pellets using NP-40 lysis buffer containing protease and phosphatase inhibitors. Protein concentration was measured using the Pierce BCA protein assay kit. Protein concentrations of samples were derived from a standard curve with BSA.
Immunoblots were performed with equal amounts of protein for all samples. This assay generated erroneous concentration values for MKN-45 and GTL-16 DTPs. Therefore, immunoblots of DTP lysates were performed by loading gels with a maximum possible sample volume, and GAPDH levels were measured as a loading control. Proteins were separated using SDS-PAGE and immunodetection was performed using standard protocols. Antibodies were from various vendors: ALDH1A1 (R&D Systems); ALDH1A2 and ALDH8A1 (Santa Cruz Biotechnology); ALDH1A3, ALDH3A1 and phospho-EGFR (Abcam); GAPDH, cleaved PARP and phospho-ATM/ATR substrates (Cell Signaling Technology); GAPDH (Pierce) and phospho-γH2A.x (Millipore).
Gene Knockdown Studies
shRNA constructs were obtained from Sigma-Aldrich. Lentivirus production was carried out in 293T cells as previously described (23) . For knockdown studies, GTL-16 cells were plated in 10 cm dishes (2 x10 6 cells per plate). Following adherence overnight, cells were infected with lentivirus or control virus in the presence of polybrene (Sigma-Aldrich) overnight. Forty-eight hours post-infection, cells re-plated, and following adherence overnight, cells were treated as described above and cell viability was assayed using the Syto 60 nucleic acid stain (LifeTechnologies). 
Quantitative PCR analysis
RNA was extracted from parental cells and DTPs using the RNeasy kit and 1µg RNA was reverse transcribed using the high capacity RNA-to-cDNA kit (Applied Biosystems). The amount of amplicon was determined using the Applied Biosystems 7500 quantitative PCR system using SYBR green as the fluorescence reporter and normalized to GAPDH. All samples were analyzed in triplicate and C t values were determined. 
ROS Assays
Results
Drug-tolerant cancer cells express the CSC marker ALDH1A1
To identify gene expression differences in the drug-tolerant subpopulation, we analyzed the MET-amplified gastric cancer cell line, MKN-45, before and after treatment with the MET kinase inhibitor crizotinib, to which these cells are highly sensitive ( Although Aldefluor is the preferred substrate for the ALDH1A1 isoform (26) , Aldefluor can be converted by other ALDH isoforms (27 Fig. 1C) . Similarly, ALDH1A1 protein expression was higher in ALDH high cells (Fig.1C) .
Increased ALDH1A1 was also observed in crizotinib-treated MKN-45 within 24h (Fig.1D) , before drug-induced apoptosis was detected ( 
ALDH is required by drug-tolerant cancer cells
To examine a functional role for ALDH in drug tolerance we utilized the drug Disulfiram (DS), which irreversibly inhibits ALDH enzymatic activity (28, 29) . DS-treated MKN-45 and GTL-16 cells exhibited no significant viability effects (Supp. Fig. 3 ), but when combined with crizotinib, DS potently eliminated crizotinib-tolerant MKN-45 and GTL-16 cells ( Fig.   2A,B) . Although a brief pre-exposure to DS modestly reduced DTPs for some cell lines it did not eliminate all DTPs, indicating that continuous DS exposure is required to substantially reduce the drug-tolerant subpopulation (Supp. exposed to DS, they were effectively eliminated (Supp. Fig. 4B ), confirming a critical requirement for ALDH for DTP survival. Multiple ALDH isoforms are increased in GTL-16 DTPs (Supp. Fig. 5A,B) , and knockdown of ALDH1A1 had no effect on drug sensitivity or DTP formation (Supp. Fig. 6A,B Fig.5D ), implicating potential redundancy.
We also tested DS with the ALDH1A1-negative EGFR mutant lung carcinoma cell line PC-9 (Supp. Fig. 5C ), which expresses other ALDH isoforms (Supp. Fig. 5A,B) . PC-9 cells are EGFR-addicted and very sensitive to treatment with the EGFR inhibitor erlotinib (22) . DS plus erlotinib effectively killed erlotinib-tolerant PC-9 cells (Fig. 2C) . PC-9-derived DTPs begin expanding as colonies when treated with erlotinib beyond 10 days (Supp. Fig. 3 A,B), while maintaining drug-tolerance. We previously described these expanded clones as drug-tolerant expanded persisters (22) , which, unlike DTPs, are relatively refractory to DS (Fig. 2C) . Consistent with the observed effects of DS on PC-9-derived DTPs, expression of several ALDH family members was increased (Suppl. Fig.5A,B) . These results implicate multiple ALDH family members in drug tolerance, and suggest that the role for ALDH in maintaining the viability of this subpopulation is most critical prior to their expansion as drug-tolerant clones.
We extended these findings to additional kinase-dependent cancer cells. dependency, combining DS with kinase inhibition substantially reduced drug-tolerant clones ( Fig. 3 A,B) . DS alone did not cause significant cell death in any tested cell lines.
A similar effect of DS was observed on DTPs derived from treating GTL-16 cells with the DNA damaging agent, etoposide (Suppl. Fig. 4C ). Gossypol, another ALDH inhibitor (30), also showed effectiveness, although with less potency than DS, in killing drug-tolerant cells (Suppl. Fig. 7A ). To exclude the possibility that the cytotoxic effect of DS reflects activity on low density cultures (DTPs), we plated GTL-16 cells and DTPs at different densities and treated with DS. Irrespective of plating density, DS effectively killed most DTPs, whereas no cytotoxic effect was observed on parental cells plated at the same densities (Suppl. Fig.   6C ). A similar analysis of PC9 parental cells revealed DS sensitivity only in DTPs (Suppl. Fig.6D ). These results collectively support the potentially broad ALDH requirement in a drug-tolerant subpopulation of cancer cells.
The drug-tolerant subpopulation experiences increased oxidative stress
The ALDH requirement in drug-tolerant cells might reflect increased levels of toxic aldehydes, resulting from peroxidation of membrane lipids (31), due to oxidative stress associated with increased reactive oxygen species (ROS). The drug-resistant properties of CSCs may reflect, in part, the activation of adaptive responses to continuous exposure to low level stress (32) , often associated with increased ROS and a DNA damage response (33) . Since mitochondria are the major source of ROS, we examined the bioenergetics of (Fig.   4C ), suggesting elevated oxidative stress in DTPs. Increased DNA damage sensor and transducer activity was also observed in DTPs (Fig. 4D) . These results suggest that ALDH high cells and DTPs utilize specific mechanisms to maintain viability under conditions of increased oxidative stress.
Disulfiram-induced killing of drug-tolerant cells requires increased ROS
ALDH enzymes function as detoxifying agents by reducing toxic aldehydes resulting from lipid peroxidation in cells undergoing oxidative stress (34, 31) . To determine whether selectively killing of drug-tolerant cells by DS reflects ALDH's role in suppressing ROSinduced DNA damage, we used the ROS scavenger, N-acetyl cysteine (NAC). In PC-9 
cells, erlotinib alone caused a 6-fold increase in ROS in DTPs, and an additional 3-fold ROS increase was observed in cells co-treated with erlotinib and DS. Significantly, the DS effect on ROS was almost completely abrogated when NAC was added (Fig. 5A) . Similar results were obtained with GTL-16-derived DTPs. A small but significant increase in ROS was observed in crizotinib/DS co-treated cells, and the addition of NAC caused a ~75% drop in ROS. NAC also reduced ROS in GTL-16 DTPs by ~60% but failed to reduce erlotinib-induced ROS in PC-9-derived DTPs (Fig 5A) . These results suggest that while kinase inhibitor treatment elevates ROS in kinase-addicted cancer cells, the drug-tolerant subpopulation utilizes ALDH to protect against ROS-mediated cell death.
We then examined DNA damage in DTPs in the presence or absence of DS and NAC. We observed significantly increased DNA damage in DTPs exposed to kinase inhibitors plus DS compared to kinase inhibitor alone, and the effects of DS on DNA damage were abrogated by NAC (Fig. 5B) . Notably, ALDH inhibition increased the turnover of some of the ALDH isoforms (Fig. 5B, Suppl. Fig. 7B ). The ROS increase in cells co-treated with kinase inhibitor and DS also triggered apoptosis of DTPs, as revealed by increased cleaved PARP in GTL-16-derived DTPs and BimS in PC-9-derived DTPs. Consistent with NAC's ability to suppress DS-induced DNA damage, NAC co-treatment also decreased cleaved PARP and BimS (Fig. 5B) . NAC is also sufficient to rescue DTPs from the lethal effects of DS (Fig. 5C) . Collectively, these results suggest that increased ALDH in the drug-tolerant subpopulation maintains sufficiently low levels of ROS to prevent apoptosis. To investigate the ability of DS to delay tumor relapse in vivo, we used a PC-9 xenograft model. The treatment regimen was first tested in vitro; thus, cells were treated with either erlotinib or DS alone or in combination, and after six days, cells were maintained with or without DS for four more days. We observed a significant growth delay in cells treated with erlotinib+DS compared to erlotinib alone, and a further delay in erlotinib+DS-treated cells that continued to receive DS (Fig. 6A) . A pharmacodynamic study of treated tumors indicated decreased p-EGFR in both erlotinib and erlotinib+DS-treated tumors (Fig. 6C ).
ALDH inhibition delays tumor relapse in xenograft mouse models
In the xenograft tumor growth study mice were divided into four groups; namely, vehicle control, DS control, erlotinib alone and erlotinib+DS groups. As expected, erlotinib was highly effective while single agent DS caused minimal efficacy (Fig. 6B , Supp. Table 2 ).
After eleven days of erlotinib alone or in combination with DS, most tumors were substantially reduced. Therefore, to assess the added effect of DS, all treatments were stopped, except for DS, which was continued until the end of the study. No significant loss in body weight was observed in mice as a result of any of the treatments (Supp.
Table 2).
We observed near complete regression of tumors with erlotinib--11/15 mice responding Table 2 ). These data indicate a highly significant (P<0.0007) delay in tumor relapse in the erlotinib+DS-treated mice compared to those treated with erlotinib alone, consistent with a role for ALDH in drug tolerance in tumors.
Discussion
We have described a drug tolerance mechanism associated with a cancer cell subpopulation derived from various tissues of origin, which involves the ALDH enzyme One of the major consequences of increased oxidative stress levels is the accumulation of DNA lesions, which can lead to apoptosis. The activation of DNA damage response (DDR) in glioma-derived CSCs at a level higher than that seen in non-CSCs may contribute to the observed resistance to ionizing radiation therapy (10) . Similarly, we detected increased double-stranded DNA breaks in our model systems, suggesting that activation of DDR may be a widely used mechanism of survival of a subpopulation of cancer cells during cancer therapy.
Other reported mechanisms of action of DS, including inhibition of P-glycoproteins involved in drug efflux, and proteasome inhibition, are seen at relatively higher DS concentrations (37, 38) . However, our findings indicating complete inhibition of phosphor-MET in MKN-45 and GTL-16 DTPs (Suppl. We propose a model (Fig. 7) implicating ALDH family members in maintaining intracellular aldehyde levels (and consequently, ROS levels) below the threshold beyond which an apoptotic response is engaged. Our findings with NAC co-treatment emphasize the critical importance of managing ROS levels for the survival of drug-tolerant cells and raise the ALDH activity is required to maintain ROS levels sufficiently low to prevent triggering of apoptosis. Inhibition of ALDH activity by DS increases ROS levels above a threshold, consequently triggering apoptosis, a process that can be suppressed by the ROS scavenger N-acetyl cysteine (NAC). 
